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PHeart Rhythm Disorders
erapamil Versus Digoxin and Acute Versus
outine Serial Cardioversion for the Improvement
f Rhythm Control for Persistent Atrial Fibrillation
artin E. W. Hemels, MD,* Trudeke Van Noord, MD,* Harry J. G. M. Crijns, MD,†
irk J. Van Veldhuisen, MD, FACC,* Nic J. G. M. Veeger, MSC,‡ Hans A. Bosker, MD,§
ns C. P. Wiesfeld, MD,* Maarten P. Van den Berg, MD,* Adelita V. Ranchor, PHD,
sabelle C. Van Gelder, MD*
roningen, Maastricht, and Arnhem, the Netherlands
OBJECTIVES The VERDICT (Verapamil Versus Digoxin and Acute Versus Routine Serial Cardioversion
Trial) is a prospective, randomized study to investigate whether: 1) acutely repeated serial
electrical cardioversions (ECVs) after a relapse of atrial fibrillation (AF); and 2) prevention of
intracellular calcium overload by verapamil, decrease intractability of AF.
BACKGROUND Rhythm control is desirable in patients suffering from symptomatic AF.
METHODS A total of 144 patients with persistent AF were included. Seventy-four (51%) patients were
randomized to the acute (within 24 h) and 70 (49%) patients to the routine serial ECVs, and
74 (51%) patients to verapamil and 70 (49%) patients to digoxin for rate control before ECV
and continued during follow-up (2  2 factorial design). Class III antiarrhythmic drugs were
used after a relapse of AF. Follow-up was 18 months.
RESULTS At baseline, there were no significant differences between the groups, except for beta-blocker
use in the verapamil versus digoxin group (38% vs. 60%, respectively, p 0.01). At follow-up,
no difference in the occurrence of permanent AF between the acute and the routine
cardioversion groups was observed (32% [95% confidence intervals (CI)] 22 to 44) vs. 31%
[95% CI 21 to 44], respectively, p  NS), and also no difference between the verapamil- and
the digoxin-randomized patients (28% [95% CI 19 to 40] vs. 36% [95% CI 25 to 48]
respectively, p NS). Multivariate Cox regression analysis revealed that lone digoxin use was
the only significant predictor of failure of rhythm control treatment (hazard ratio 2.2 [95% CI
1.1 to 4.4], p  0.02).
CONCLUSIONS An acute serial cardioversion strategy does not improve long-term rhythm control in
comparison with a routine serial cardioversion strategy. Furthermore, verapamil has no
beneficial effect in a serial cardioversion strategy. (J Am Coll Cardiol 2006;48:1001–9)
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.05.043© 2006 by the American College of Cardiology Foundation
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ourrently, rate control is the recommended treatment for
he majority of patients with atrial fibrillation (AF), pro-
ided they are not symptomatic (1,2). However, the ran-
omized rate versus rhythm control studies did not deal
ith patients highly symptomatic with the arrhythmia (1,2).
n these patients, rhythm control with cardioversion and
ntiarrhythmic drugs or non-pharmacological interventions
s desirable (3,4). Still, long-term maintenance of sinus
hythm (SR) is cumbersome. This is mainly caused by atrial
lectrical and structural remodeling (5–7). Maintenance of
R is associated with reversal of remodeling (8–12). The
F-induced electrical remodeling takes only half a day, and
t is considered reversible within 2 to 5 days (9–12).
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niversity of Groningen, Groningen, the Netherlands; †University Hospital, Maas-
richt, the Netherlands; ‡Trial Coordination Center, Groningen, the Netherlands;
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are Research, Groningen, the Netherlands. The study was supported by the
etherlands Heart Foundation (98-105), Medtronic Bakken Research Center B.V.,
itatron, and AstraZeneca Sweden.r
Manuscript received January 25, 2006; revised manuscript received April 10, 2006,
ccepted May 2, 2006.herefore, in patients undergoing cardioversion for persis-
ent AF, maintaining SR for at least a few days is needed to
evelop reversed remodeling. In addition, an eventual re-
apse of AF must be stopped within hours to avoid recur-
ence of electrical remodeling (12,13).
Atrial calcium overload and reduction of L-type calcium
hannels are the primary cause of electrical and contractile
emodeling (6,7,14). Prevention of intracellular calcium over-
oad by calcium antagonists may decrease intractability of AF
y preventing these remodeling processes. In a serial cardio-
ersion strategy, remodeling may happen again and again, and
n this setting verapamil has not been tested before.
The development of a safe and effective pharmacological
hythm-control strategy would have a major impact on the
reatment of AF. Considering the above, we hypothesized that
n acute serial cardioversion strategy, by enhancing and con-
olidating reversed remodeling, could improve arrhythmia
utcome in persistent AF. In addition, we reasoned that in this
etting verapamil, by preventing repeated intracellular calcium
verload, may enhance reversed remodeling and help to slow
ecurrent remodeling with each recurrence. Therefore, we
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Rhythm Control for Persistent AF September 5, 2006:1001–9nvestigated whether during a serial electrical cardioversion
ECV) strategy, 1) acute cardioversion of subacute recurrences,
nd 2) prevention of intracellular calcium overload by verap-
mil in case relapses occur, will decrease intractability of
ersistent AF. In addition, the influence of the acute strategy
n quality of life was investigated.
ETHODS
tudy design. Seven centers in the Netherlands partici-
ated in the study (Appendix). All patients gave written
nformed consent. The institutional review boards of all
ospitals approved the study protocol. The study started in
une 2001. Total follow-up was 18 months in all patients.
Only patients with persistent AF without contraindica-
ion for oral anticoagulation were included. Persistent AF
as defined as non–self-terminating arrhythmia and requir-
ng ECV to obtain SR (15). Patients were excluded if the
urrent episode of AF had lasted longer than 1 year or if any
revious ECV was unsuccessful. A maximum of 1 previous
CV during the last year was allowed. Patients were also
xcluded if they had unstable angina pectoris, a recent
yocardial infarction or cardiac surgery (4 weeks), current
nfection or thyroid disturbances, atrial flutter, a concurrent
ntreated medical condition, were unlikely to comply with
he protocol, heart failure New York Heart Association
NYHA) functional class III or IV, current or previous
reatment with amiodarone, or a pacemaker.
This was a randomized open study. Patients were ran-
omized to: 1) acute (using transtelephonic monitoring to
dentify relapses of AF twice a day and guarantee acute
CVs within 24 h) or routine (rhythm follow-up at the
utpatient clinic) serial ECVs; and 2) verapamil (120 to 360
g daily) or digoxin (0.125 to 0.25 mg daily, after loading,
epending on age, heart rate, and renal function) for rate
ontrol before ECV and continued during total follow-up
2  2 factorial design) (Fig. 1). The target was a resting
eart rate 100 beats/min (monitored with a 12-lead
esting electrocardiogram) (2). If patients were treated with
erapamil or digoxin before inclusion, the drugs were
iscontinued after randomization, and patients received
erapamil or digoxin according to the randomization. If
atients were using a beta-blocker, they were allowed to
ontinue this drug.
From 4 weeks before until 4 weeks after ECV, all patients
Abbreviations and Acronyms
AF  atrial fibrillation
CI  confidence interval
ECV  electrical cardioversion
INR  international normalized ratio
IRAF  immediate reinitiation of atrial fibrillation
LV  left ventricle/ventricular
NYHA  New York Heart Association
SR  sinus rhythmeceived phenprocoumon or acenocoumarol (target interna- eional normalized ratio [INR] 2.5 to 3.5, according to the
etherlands guidelines). Anticoagulation was monitored at
regional center of The Netherlands Thrombosis Services,
hich specializes in monitoring anticoagulant treatment in
utpatients. If SR was present at 1 month, the oral antico-
gulant could be stopped or changed to aspirin (80 to 100
g daily), depending on stroke risk factors. Two weeks after
andomization, the patients visited the outpatient clinic for
hysical examination, transthoracic echocardiography, and a
4-h Holter monitor to assess rate control. The ECV was
cheduled 1 month after randomization and was performed
nly if anticoagulant treatment had been adequate. After
his first ECV, patients followed their randomized ECV
trategy, including those who had spontaneous conversion
o SR before the first ECV. All patients continued verap-
mil or digoxin throughout the study.
Electrical cardioversion was performed during light gen-
ral anesthesia by using 20 mg of etomidate intravenously.
calibrated mono- or biphasic defibrillator, which could
tore 360 or 200 J of energy, respectively, was used as a
ardioversion device. We started with 100 or 50 J of stored
nergy, respectively. Thereafter, energy load of successive
hocks was doubled until SR was restored or after 2
ttempts at the highest level. All shocks were applied to the
hest in an anterior-lateral paddle configuration. Immediate
utcome of the shock was monitored by continuous 12-lead
lectrocardiogram for 5 min. Post-shock rhythm monitor-
ng was secured by telemetry for 4 h.
Patients visited the outpatient department 1, 3, 6, 12, 15,
nd 18 months after cardioversion. At each visit, com-
laints, cardiovascular events, physical examination, and a
2-lead electrocardiogram were recorded. Additional visits
ere performed 1 month after each re-ECV. During the
rst month, patients randomized to the acute group mon-
tored and transmitted their heart rhythm twice a day to the
olter analysis department of the University Medical Cen-
er Groningen by using a wrist-electrocardiogram recorder.
wo experienced Holter technicians judged all wrist-
igure 1. Study flow chart. AAD  antiarrhythmic drug; AF  atrial
brillation; ECV  electrical cardioversion; IRAF immediate reinitia-
ion of AF; TTM  transtelephonic monitoring.lectrocardiograms. After this month, patients received
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September 5, 2006:1001–9 Rhythm Control for Persistent AFnstructions concerning recurrence detection, and in case of
relapse, they were instructed to come to the hospital
mmediately in order to perform ECV within 24 h. After
ach recurrence after the first month, they used the wrist-
lectrocardiogram recorder twice a day for another 2 weeks.
If in the acute cardioversion group the first study ECV
as unsuccessful, amiodarone was instituted according to
he schedule mentioned in the following text. In case of a
elapse, ECV was repeated as soon as possible, but always
ithin 24 h after relapse of AF. The first month after the
rst cardioversion, no antiarrhythmic drugs were instituted
except for amiodarone for 2 weeks; see the text that
ollows), regardless of the number of preceding ECVs. In
he case of an unsuccessful re-ECV (i.e., no SR restored
uring ECV, or untreatable immediate reinitiation of atrial
brillation [IRAF], or a relapse of AF within 4 h after
CV), patients received amiodarone: immediately after
nsuccessful (repeat) ECV, 300 mg amiodarone intrave-
ously in 30 min, followed by 1,200 mg during the next
4 h. Repeat ECV was performed 24 h after loading with
miodarone. In the case of chemical conversion or successful
epeat ECV, amiodarone was continued orally at 600 mg
aily for 2 weeks. Amiodarone was used as the first-choice
rug because we expected that this drug would most
ffectively prevent recurrences. Amiodarone was used as a
emporary drug; i.e., after maintaining SR for at least 2
eeks, the drug was stopped. In the case of an unsuccessful
epeat ECV, amiodarone orally (600 mg daily) was contin-
ed for 4 weeks. Subsequently, in the case of no chemical
onversion, ECV was repeated (see routine cardioversion
roup). In the case of a relapse after 1 month, prophylactic
ntiarrhythmic drugs were instituted (see routine cardiover-
ion group), but the acute strategy still applied. If the
ombination of a class III antiarrhythmic drug with verap-
mil or digoxin led to symptomatic sinus bradycardia, AV
onduction disturbances, or low blood pressure, dosages of
erapamil or digoxin were lowered or discontinued.
In the routine cardioversion group, after the first cardio-
ersion, no antiarrhythmic drugs were instituted. After a
elapse, patients started with sotalol (240 to 320 mg daily)
nd, in the case of another relapse within 3 months,
miodarone (600 mg daily for 4 weeks before ECV, fol-
owed by 200 mg daily after ECV) was instituted. Relapses,
hich occurred 3 months of SR, were interpreted as
ailure of the antiarrhythmic drug presently instituted, and
hese patients continued to the next drug. Sotalol, but not
miodarone, was instituted in-hospital during 24 h of tele-
etric monitoring. We did use sotalol and not amiodarone as
first-line treatment in case of a recurrence to comply as
uch as possible with the routines in our clinic. Obviously,
miodarone would have prevented recurrences better than
otalol or flecainide, but it was not used to avoid as much as
ossible its potential side effects (3). In the case of a relapse
f AF, a repeat ECV was scheduled as hospital routines
ictated, but always within 4 to 6 weeks. sThe primary end point was permanent AF, which was
efined as acceptance of AF if patients experienced a relapse
f AF within 3 months after cardioversion or shock failure
hile on amiodarone, provided adequate plasma levels
amiodarone and desethylamiodarone cumulative plasma
evels 2.0 mg/l), or if patients had a relapse of AF and
ntiarrhythmic drug-related side effects, or if patients re-
used another ECV.
uality of life. Quality of life was assessed using the
edical Outcomes Study Short-Form health survey (SF-
6) questionnaire. The SF-36 is a standardized, validated,
eneric health survey that has been frequently used in
rrhythmia studies. The SF-36 has been translated and
alidated in the Netherlands (16). Quality of life was
etermined at baseline and at the end of follow-up.
tatistical analysis. The primary objective was to test our
ypothesis that acute cardioversion after a relapse of AF will
ecrease intractability of AF, i.e., permanent AF. This study
as originally powered to detect a relative difference of 50%
n permanent AF, which was based on our results from a
revious cardioversion study (17). With 40% permanent AF
n the acute cardioversion group versus 60% in the routine
ardioversion group after 18 months of follow-up, 240
atients were needed to reach statistical significance with a
ower of 80% and alpha of 0.05 (two-sided). The present
anuscript describes the final results of the VERDICT
Verapamil Versus Digoxin and Acute Versus Routine
erial Cardioversion Trial) after 144 patients had completed
he study, at the time of the planned interim analysis. With
2% versus 31% permanent AF in the acute versus the
outine cardioversion group, it was decided to stop further
nclusion of patients. A secondary aim of this study was to
nvestigate whether prevention of intracellular calcium over-
oad by verapamil (but not by digoxin) will reduce perma-
ent AF. The baseline characteristics of patients were
ompared with chi-square tests and t tests. For all time-to-
vent analyses, Kaplan-Meier estimates were used and were
ompared by the log-rank test. Univariate and multivariate
ox regression analyses were performed to determine pre-
ictors of permanent AF. For categorization of continuous
ariables, cutoff points were chosen on the basis of clinical
elevance or the median value. The univariately analyzed
ariables included gender, age, hypertension, coronary artery
isease, valvular heart disease, diabetes, heart failure, car-
iomyopathy, respiratory disease, AF duration, previous
CV(s), previous antiarrhythmic drug use, body mass index,
lood pressure, heart rate, echocardiographic atrial and
entricular dimensions, medication use (including verapamil
nd digoxin use), and ECV strategy (acute versus routine).
ll univariate variables with p  0.10 were added to the
ultivariate model. In multivariate models, interaction was
nvestigated. All tests performed in order to test the (null-)
ypothesis of no treatment difference were two-sided. Pa-
ient data were used in accordance with the intention-to-
reat principle. A p  0.05 was considered statistically
ignificant. For all analyses, commercially available com-
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Rhythm Control for Persistent AF September 5, 2006:1001–9uter software (Statistical Analysis System version 6.12,
AS Institute, Cary, North Carolina) was used.
ESULTS
haracteristics of the patients. A total of 144 patients
ere enrolled in the study. At inclusion (1 month before
CV), 74 (51%) were randomized to the acute and 70
49%) to the routine cardioversion group. Furthermore, 74
51%) patients were randomized to verapamil and 70 (49%)
o digoxin for rate control (Fig. 1).
able 1. Baseline Characteristics of Patients Randomized to the
o Digoxin Versus Verapamil
ge, yrs
ale gender, no. (% of patients) 4
otal history of AF, days 13
uration of current episode of AF, days 6
revious ECV(s), no. (% of patients)
0 6
1 1
2
inus rhythm duration after last ECV, months 1
oronary artery disease, no. (% of patients) 1
Old myocardial infarction, no. (% of patients)
alve disease, no. (% of patients)
Aortic
Mitral 1
Aortic and mitral
ardiomyopathy, no. (% of patients)
Dilated
Hypertrophic
istory of hypertension, no. (% of patients) 3
istory of chronic obstructive lung disease, no. (% of patients) 1
istory of diabetes mellitus, no. (% of patients)
o apparent heart disease, no. (% of patients) 2
eart failure, no. (% of patients)
NYHA functional class I 6
NYHA functional class II
omplaints, no. (% of patients) 5
Dyspnea 4
Fatigue 3
Palpitations 2
revious class I and III AADs, no. (% of patients) 1
edication use, no. (% of patients)
ACE inhibitor or ARB 3
Diuretics 2
Lipid-lowering drugs 1
Acenocoumarol or phenprocoumon 7
lood pressure, mm Hg
Systolic
Diastolic
ody mass index
chocardiographic findings, mm
Size of left atrium long axis
Left ventricular end-diastolic diameter
Left ventricular end-systolic diameter
Septal thickness
Posterior-wall thickness
Fractional shorteningAD  antiarrhythmic drug; ACE  angiotensin-converting enzyme; AF  atrial fib
YHA  New York Heart Association.cute versus routine serial cardioversion. There were no
ignificant differences in baseline characteristics (Table 1). In
he acute and routine groups, 43 (58%) and 39 (56%) patients,
espectively, had an unsuccessful ECV or a subacute recurrence
f AF30 days (pNS) (Fig. 2). Late recurrences30 days
fter the first study ECV occurred in 20 (27%) and 17 (24%)
f the acute and routine randomized patients, respectively (p
S). Nine (12%) and 10 (14%) patients maintained SR during
he total follow-up, respectively (p  NS). After 18 months,
o difference in permanent AF between both groups was
Versus Routine Serial Cardioversion Group and Randomized
te
74)
Routine
(n  70)
Digoxin
(n  70)
Verapamil
(n  74)
11 66  8 65  11 65  8
) 43 (61) 46 (66) 43 (58)
–730) 113 (43–285) 140 (51–716) 117 (42–304)
–138) 61 (33–125) 56 (32–124) 70 (30–138)
) 58 (83) 54 (77) 64 (87)
) 11 (16) 13 (19) 8 (11)
1 (1) 3 (4) 2 (3)
42) 11 (1–53) 15 (3–47) 6 (1–46)
) 11 (16) 13 (19) 9 (12)
7 (10) 8 (11) 6 (8)
4 (6) 2 (3) 2 (3)
) 8 (11) 9 (13) 11 (15)
2 (3) 0 (0) 3 (4)
3 (4) 2 (3) 4 (5)
2 (3) 2 (3) 2 (3)
1 (1) 0 (0) 2 (2)
) 30 (43) 29 (41) 38 (51)
) 4 (6) 7 (10) 9 (12)
8 (11) 5 (7) 8 (11)
) 26 (37) 25 (36) 27 (36)
) 66 (94) 65 (93) 70 (95)
4 (6) 5 (7) 4 (5)
) 58 (83) 56 (80) 61 (82)
) 36 (51) 37 (53) 42 (57)
) 36 (51) 27 (39) 39 (53)
) 18 (26) 23 (33) 21 (28)
) 11 (16) 10 (14) 11 (15)
) 25 (36) 25 (36) 36 (49)
) 27 (39) 27 (39) 25 (34)
) 10 (16) 12 (17) 9 (12)
0) 70 (100) 70 (100) 74 (100)
20 142  21 140  19 143  22
10 87  15 85  10 88  15
5 29  6 29  5 29  6
7 46  6 45  6 46  6
6 52  6 52  6 51  6
8 36  8 37  8 35  7
2 11  3 11  3 10  2
1 10  2 10  2 10  2
9 31  9 30  10 32  8Acute
Acu
(n 
65 
6 (62
8 (47
0 (27
0 (81
0 (14
4 (5)
3 (3–
1 (15
7 (9)
0 (0)
2 (16
1 (1)
3 (4)
3 (4)
0 (0)
7 (50
2 (16
5 (7)
6 (35
9 (93
5 (7)
9 (80
3 (58
0 (41
6 (35
0 (14
6 (49
5 (34
0 (14
4 (10
141 
86 
29 
45 
51 
36 
11 
10 
31 rillation; ARB  angiotensin receptor blocker; ECV  electrical cardioversion;
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September 5, 2006:1001–9 Rhythm Control for Persistent AFbserved (32% [95% confidence interval (CI) 22 to 44] [n 
4] vs. 31% [95% CI 21 to 44] [n  22], p  0.85) (Fig. 3),
espite more ECVs in the acute versus the routine group
median 3 vs. 2, p  0.05, and 3 ECVs in 54% vs. 33%,
espectively; p  0.01).
igure 2. Recurrence pattern and treatment of recurrent atrial fibrillation
R  sinus rhythm; other abbreviations as in Figure 1.igure 3. Freedom from permanent atrial fibrillation in acutely versus
outinely treated patients. Abbreviations as in Figure 1. aNo significant differences in medication use between both
roups at ECV, and after 1 and 18 months of follow-up
ere present, except for amiodarone use after 1 month (40%
s. 9% of patients in the acute versus the routine cardiover-
ion group, respectively; p  0.001) and sotalol use at 18
onths (4% vs. 23%, respectively; p  0.05) (Table 2).
miodarone was started in 16 patients because of shock
ailure (12 vs. 4 patients in the acute vs. the routine group,
espectively; p  0.05), in 21 patients because of IRAF (15
s. 6 patients in the acute versus the routine group, respec-
ively; p  0.05), and in 36 patients because of repeated
g the first 4 weeks in the acute versus routine group. SF  shock failure;
able 2. Medication During the Study of Patients Randomized
o the Acute Versus Routine Serial Cardioversion Group
Drug Strategy
At
ECV1*
1 Month After
ECV1*
Permanent
AF/EoS*
igoxin Acute 37 (50) 37 (50) 27 (37)
Routine 33 (47) 33 (47) 30 (43)
erapamil Acute 37 (50) 30 (40) 27 (37)
Routine 37 (53) 32 (46) 21 (30)
eta-blocker Acute 37 (50) 30 (41) 26 (35)
Routine 33 (47) 30 (43) 22 (31)
otalol Acute 0 (0) 0 (0) 3 (4)
Routine 0 (0) 4 (5) 16 (23)†
miodarone Acute 0 (0) 30 (40) 28 (38)
Routine 0 (0) 6 (9)† 28 (40)
Values expressed as n (%) of patients; †p  0.05 acute versus routine group.
ECV1  first-study electrical cardioversion; EoS  end of study; other abbrevi-
tions as in Table 1.
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Rhythm Control for Persistent AF September 5, 2006:1001–9ecurrences (15 vs. 21 patients in the acute vs. routine group,
espectively; p  NS). Mean amiodarone dose and plasma
evels of amiodarone and desethylamiodarone were not
ignificantly different between successfully (1.3  0.6 mg/l
nd 0.9  0.3 mg/l, respectively) and unsuccessfully (1.4 
.4 mg/dl and 0.8  0.2 mg/dl) treated patients. Four
atients refused further amiodarone therapy. Side effects of
miodarone led to discontinuation in 15% of patients (skin
ash [n  4], excessive prolongation of QT duration
n  2], gastrointestinal problems [n  2], thyreotoxicosis
n  1], blurred vision [n  1], and elevated liver enzymes
3 times the upper level of normal [n  1]). At the end of
ollow-up, 77% of patients (n  111) still used phenprocoumon
r acenocoumarol, 5% (n  7) were on aspirin therapy, and
8% (n  26) discontinued their anticoagulant therapy.
fficacy of acutely repeated cardioversions. In the acute
roup, most re-ECVs were performed during the first week
fter the initial ECV (37 re-ECVs during the first week,
nd 12, 6, and 5 re-ECVs during the second, third, and
ourth weeks after the initial ECV, respectively). Median
ime spent in SR between the first ECV and the first relapse
able 3. Medication During the Study of Patients Randomized
o the Digoxin Versus Verapamil
Drug Strategy
At
ECV1*
1 Month After
ECV1*
Permanent
AF/EoS*
igoxin Digoxin 70 (100) 68 (97) 54 (77)
Verapamil 0 (0)† 4 (6)† 3 (4)†
erapamil Digoxin 0 (0) 0 (0) 1 (1)
Verapamil 69 (93)† 63 (85)† 47 (64)†
eta-blocker Digoxin 42 (60) 34 (48) 24 (34)
Verapamil 28 (38)† 32 (43) 24 (32)
otalol Digoxin 0 (0) 2 (3) 12 (17)
Verapamil 0 (0) 1 (1) 7 (10)
miodarone Digoxin 0 (0) 18 (25) 31 (44)
Verapamil 0 (0) 19 (25) 25 (34)
Values expressed as n (%) of patients; †p  0.05 digoxin versus verapamil group.
Abbreviations as in Tables 1 and 2.Figure 4. Time to first relapse in the acute group betwas 3 (0 to 19) days; between the second ECV (re-ECV1)
nd the second relapse, 3 (0 to 119) days; and between
e-ECV2 and the third relapse, 9 (1 to 478) days. Re-ECV1
n the acute group was performed24 h in 94% of patients,
e-ECV2 in 81% of patients 24 h, and re-ECV3 in 70%
f patients. Thereafter, the number of patients with an acute
e-ECV sharply decreased. Acute repeated ECVs were
ostponed predominantly because of unsuccessful ECVs
ecessitating amiodarone loading (Fig. 2). Progressive in-
rease in duration of the repetitive episodes of SR were
bserved in 38% who underwent a second ECV (re-ECV1),
n 38% undergoing a third ECV (re-ECV2), and in 14%
ndergoing a fourth ECV (re-ECV3). Atrial fibrillation was
redominantly accepted because of failure of the strategy
71% vs. 95% in the acute vs. the routine group, respectively;
 NS). More refusals for a repeated ECV were observed
n the acute group (29% vs. 5%, respectively; p  0.05).
erapamil versus digoxin. No significant differences in
aseline characteristics were present (Table 1). To obtain
dequate rate control, more patients in the digoxin group
ere treated with additional beta-blocker therapy (60% vs.
8%, respectively; p  0.01) (Table 3). During 24-h Holter
onitoring performed 2 weeks after inclusion mean heart
ate was comparable in the verapamil versus the digoxin
roup: 82  12 beats/min versus 84  13 beats/min,
espectively. Spontaneous conversion occurred in 12% (n 
) of patients on verapamil versus 1% (n  1) of patients on
igoxin (p  0.01). There was no significant difference in
he time to the first relapse (Fig. 4). After 18 months of
ollow-up, AF was accepted in 28% (n 21) (95% CI 19 to
0) versus 36% (n  25) (95% CI 25 to 48) of the
erapamil- versus the digoxin-treated patients, respectively
p  0.33) (Fig. 5), despite more ECVs in the digoxin
roup (median of 3 vs. 2, p  0.001, and 3 ECVs in 60%
s. 28% in the digoxin vs. verapamil group, respectively; p
.001). A total of 19 patients maintained SR after 1 ECVeen digoxin- versus verapamil-treated patients.
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September 5, 2006:1001–9 Rhythm Control for Persistent AF13 patients randomized to verapamil vs. 6 patients random-
zed to digoxin; p  NS). At the end of follow-up, 17% of
atients in the digoxin group versus 10% in the verapamil
roup used sotalol, and 44% in the digoxin group versus
4% in the verapamil group were treated with amiodarone
both p  NS) (Table 3).
hromboembolic complications and bleeding. Bleeding
ccurred in 6 patients (4%) during oral anticoagulant
herapy (all patients had an INR 3.0). Two patients (1%)
ad a transient ischemic attack. There were no differences in
nticoagulant therapy and complications between the
roups.
arameters related to occurrence of permanent AF. In
he total patient group, multivariate analysis revealed that
he use of digoxin monotherapy was the only parameter
elated to a higher occurrence of permanent AF (adjusted
azard ratio 2.2 [1.1 to 4.4], p  0.02) (Table 4). From
ultivariate analysis, there was no evidence of interaction
etween ECV strategy (acute or routine) and drug strategy
verapamil or digoxin).
utcome of cardioversions. First study ECV was per-
ormed in 129 patients. In 15 patients, no ECV was
erformed because of spontaneous conversion (n  10),
eart failure (n  1, verapamil acute group), refusal (n  2,
igure 5. Freedom from permanent AF in digoxin- versus verapamil-
reated patients. Abbreviations as in Figure 1.
Table 4. Predictors of Occurrence of Permanen
Univariate
Model
HR 95%
Lone digoxin use 2.4 1.2–4
Diastolic BP 86 mm Hg 1.9 1.0–3
ACE inhibitor or ARB use 0.5 0.3–1
Total AF duration (yrs) 1.1 1.0–1No interaction term was found statistically significant.
BP  blood pressure; CI  confidence interval; HR  hazarderapamil routine group and digoxin routine group), stroke
n  1, digoxin routine group), and respiratory insufficiency
n  1, verapamil routine group) before the planned
ardioversion. First study ECV was successful in 111
atients (86%) and unsuccessful in 8% because of shock
ailure and in 6% because of IRAF. No significant differ-
nces in this figure were observed between digoxin- and
erapamil-randomized patients.
uality of life. There were no significant differences in
uality of life between the acute and the routine cardiover-
ion groups. At the end of follow-up, scores on general
ealth perception and bodily pain were significantly higher
n the routine group compared to the acute group. At that
ime, the acute group showed a significant improvement on
subscales (physical role limitations, social functioning, and
itality), whereas patients randomized to the routine group
emonstrated a significant improvement on 6 subscales. No
ignificant differences between verapamil- and digoxin-
andomized patients were observed at baseline or at 18
onths of follow-up. At the end of follow-up, the digoxin
roup showed a significant improvement on 5 subscales, and
he verapamil group on 3 subscales (data not shown). In
atients who were in SR at 18 months, quality of life was
ot significantly different compared to patients in AF.
ISCUSSION
his study shows that an acute serial cardioversion strategy
oes not improve the outcome of rhythm-control therapy.
lso, in a serial cardioversion strategy, verapamil does not
ave beneficial effects. Finally, digoxin monotherapy should
ot be instituted in patients in whom rhythm control is
ndicated.
cute serial cardioversion. This study does not show any
dvantage of an acute serial cardioversion strategy. Theo-
etically, an acute cardioversion strategy may, by enhancing
nd consolidating reversed remodeling, improve arrhythmia
utcome in persistent AF managed with serial cardiover-
ions (9–12). Similar to us, Fynn et al. (13) designed an
arly repeated internal ECV strategy to support recovery
rom electrical remodeling and to reduce subsequent AF
ecurrences. Although they could demonstrate reversal of
lectrical remodeling, no beneficial effect on maintenance of
R was observed, comparable to our findings. Several
xplanations may be responsible. First, time to repeated
Multivariate
Model
p HR 95% CI p
0.013 2.2 1.1–4.4 0.02
0.06 1.9 1.0–3.7 0.054
0.06
0.07t AF
CI
.7
.6
.0
.1ratio; other abbreviations as in Tables 1 and 2.
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Rhythm Control for Persistent AF September 5, 2006:1001–9ardioversion may have been too long. Even though re-
eated cardioversions were performed within 24 h in the
ajority of the patients in both studies after the first and
econd re-ECV, that may not have been early enough to
ucceed with such a strategy. The delay, in part, was caused
y the occurrence of shock failure and/or IRAF, necessitat-
ng amiodarone loading, and by the patient’s (ultimate)
efusal of repeated ECV. Second, the time in SR after the
rst, second, and third cardioversion may not have been
nough to overcome remodeling. In line with this, Tieleman
t al. (12) showed that flecainide may recover its antiar-
hythmic conversion efficacy after cardioversion of AF, but
nly if AF relapses last 10 h after SR has lasted for more
han 4 days. Third, other factor(s), e.g., structural remod-
ling, may be present that require a stronger antiarrhythmic
ffect to overcome relapses of AF, if reversible at all (18,19).
ecent experimental data further substantiated the impor-
ance of factor(s) other than electrical remodeling alone for
he persistence of AF. Todd et al. (20) demonstrated that
equential 4-week periods of maintained AF with 2 days of
R in between, increased AF stability and inducibility
ndependent of the baseline atrial effective refractory period.
he latter suggests that despite acute cardioversions, con-
ecutive episodes of AF cumulatively may increase the
egree of remodeling, prohibiting complete reversal of
structural) remodeling.
alcium-channel blockade for prevention of AF. Ex-
erimentally, prevention of calcium overload by calcium
ntagonists may decrease intractability of AF by preventing
emodeling processes (21). Although effective if prescribed
n combination with antiarrhythmic drugs (22–24), vera-
amil monotherapy seems ineffective to prevent subacute
ecurrences (25,26). The discrepancy with experimental data
ay relate to the fact that in patients, calcium-lowering
reatment is almost always started after the start of AF (27).
n a serial cardioversion strategy, remodeling may happen
gain and again, and in this setting verapamil has not been
ested before. Unfortunately, this strategy also did not
emonstrate a beneficial effect of verapamil, and also not for
he occurrence of IRAF, as has previously been described
28). There are several explanations for this disappointing
esult. First, in order to obtain adequate rate control, in 60%
f the patients randomized to digoxin, a beta-blocker was
dded. Beta-blockers also lower intracellular calcium and
ay thus have ameliorated outcome in the digoxin arm. On
he other hand, Bertaglia et al. (29) observed that pre-
reatment with verapamil and amiodarone prevented elec-
rical remodeling, whereas the combination of metoprolol
nd amiodarone only accelerated recovery of electrical re-
odeling. Second, as discussed in the preceding text,
onsecutive episodes of AF cumulatively increase the degree
f remodeling, prohibiting prevention of remodeling by
alcium-lowering therapy (20). The previously described
rofibrillatory effects of verapamil (30), however, were not
bserved. Multivariate analysis showed that patients treated Gith digoxin as monotherapy more frequently relapsed into
ermanent AF.
uality of life. Quality of life is significantly reduced in
atients with AF and is not importantly affected by a rate-
r rhythm-control strategy (1,16). In this study, in all
andomized groups, several subscales of the SF-36 improved
uring follow-up whether or not SR was maintained. Thus,
oth adequate rate control and successful rhythm control
nduced a comparable improvement in quality of life. This
mprovement may be explained, at least in part, by the fact
hat at baseline, 4 weeks ahead of the first-study ECV,
uality of life was assessed before adequate rate control was
btained. This also may clarify why we did not observe any
eneficial effect of SR. Two SF-36 domains were signifi-
antly higher in the routine compared to the acute ECV-
andomized patients. During follow-up, however, improve-
ent occurred on 6 subscales in the routine group versus 3
n the acute group. This may be a sign that an acute ECV
trategy impairs quality of life.
tudy limitations. This is a relatively small study. A
eplication of our study, possibly in the setting of non-
nferiority, would be of help in establishing an optimal
hythm-control strategy. Furthermore, the acute serial car-
ioversion strategy, including acutely repeated cardioversion
ithin 24 h, could not always be accomplished, either
ecause of shock failure or IRAF, or patient refusal. This,
owever, is an important finding indicating that an acute
erial cardioversion strategy is not feasible in clinical prac-
ice. The routine arm, like the acute arm, might have
enefited from the temporary use of amiodarone to suppress
ubacute recurrences, to the effect that maybe the routine
rm would have shown even better results than the acute
rm. However, we felt not justified to use amiodarone in the
outine arm because it was not part of the clinical routine at
he time of the study, and we wanted to avoid the adverse
ffects of chronic amiodarone as much as possible. Finally,
he verapamil hypothesis also could not be tested thoroughly
ecause, for clinical reasons, beta-blockers had to be insti-
uted as an additional rate-control drug in the digoxin-
andomized patients. Beta-blockers also have calcium-
owering capacities.
onclusions. An acute serial cardioversion strategy does
ot improve rhythm control. Furthermore, verapamil has no
eneficial effect in a serial cardioversion strategy. Therefore,
he role of calcium-lowering drugs in preventing AF-
nduced electrical remodeling in clinical practice, which in
he recent past has been much emphasized, is at least
rguable.
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